The CIBMTR score for acute myeloid leukemia (AML) helps estimate a patient's 3-year overall survival probability after undergoing hematopoietic stem cell transplantation (HSCT). It involves assessing five critical factors:

- Disease Group:
  - Primary induction failure or duration of first complete remission > 6 months
  - Duration of first complete remission < 6 months

- Cytogenetics Prior to HSCT:
  - Good or intermediate
  - Poor

- HLA Match Group:
  - HLA identical sibling or well matched or partially matched unrelated
  - Mismatched unrelated
  - Related other than HLA identical sibling

- Circulating Blasts:
  - Absent
  - Present

- Karnofsky or Lanksy Scale:
  - 90-100
  - < 90

For each category, the patient's situation is mapped to a score: 

- Disease Group: 0 for the first option, 1 for the second
- Cytogenetics Prior to HSCT: 0 for good or intermediate, 1 for poor
- HLA Match Group: 0 for HLA identical sibling or well matched, 1 for mismatched unrelated, 2 for related other than HLA identical sibling
- Circulating Blasts: 0 if absent, 1 if present
- Karnofsky or Lanksy Scale: 0 if 90-100, 1 if < 90

The CIBMTR score is the sum of these individual scores, yielding a total score between 0 and 6. This total score determines the patient's survival probability:

- Score of 0: 42% 3-year survival probability
- Score of 1: 28% 3-year survival probability
- Score of 2: 15% 3-year survival probability
- Score of 3 or higher: 6% 3-year survival probability

This scoring provides a structured way to evaluate risk, where higher scores signify unfavorable prognostic factors and suggest lower survival chances. The results can inform clinical decisions and discussions with patients regarding their treatment outlook.

The CIBMTR score, or the Center for International Blood and Marrow Transplant Research score, is a prognostic scoring system specifically designed for patients with acute myeloid leukemia (AML) who are undergoing hematopoietic cell transplantation (HCT). This calculator is used to predict the risk of relapse and overall survival after HCT. It takes into account factors such as age, disease status at transplantation, cytogenetic risk, and donor type. The CIBMTR score is particularly useful in guiding clinical decision-making and patient counseling regarding the potential benefits and risks of HCT. It is not applicable to AML patients who are not candidates for HCT or those with other types of leukemia.